# A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

> **NCT05100628** · PHASE1 · TERMINATED · sponsor: **Noxopharm Limited** · enrollment: 9 (actual)

## Conditions studied

- Metastatic Soft-tissue Sarcoma

## Interventions

- **DRUG:** NOX66
- **DRUG:** NOX66
- **DRUG:** NOX66
- **DRUG:** NOX66
- **DRUG:** Doxorubicin

## Key facts

- **NCT ID:** NCT05100628
- **Lead sponsor:** Noxopharm Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-02-11
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-26
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Slow recruitment
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05100628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05100628, "A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05100628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*